NewslettersHematopoiesis News Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA Gene Overexpression By Noshin Noorjahan - April 9, 2024 0 Syros Pharmaceuticals announced that the US FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed AML with RARA overexpression. [Syros Pharmaceuticals] Press Release